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Endothelial-vasoprotective effects of high-density lipoprotein are
impaired in patients with type 2 diabetes mellitus but are
improved after extended-release niacin therapy
Abstract
BACKGROUND: High-density lipoprotein (HDL)-raising therapies are currently under intense
evaluation, but the effects of HDL may be highly heterogeneous. We therefore compared the endothelial
effects of HDL from healthy subjects and from patients with type 2 diabetes mellitus and low HDL
(meeting the criteria for metabolic syndrome), who are frequently considered for HDL-raising therapies.
Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the
endothelial effects of HDL. METHODS AND RESULTS: HDL was isolated from healthy subjects
(n=10) and patients with type 2 diabetes (n=33) by sequential ultracentrifugation. Effects of HDL on
endothelial nitric oxide and superoxide production were characterized by electron spin resonance
spectroscopy analysis. Effects of HDL on endothelium-dependent vasodilation and early endothelial
progenitor cell-mediated endothelial repair were examined. Patients with diabetes were randomized to a
3-month therapy with ER niacin (1500 mg/d) or placebo, and endothelial effects of HDL were
characterized. HDL from healthy subjects stimulated endothelial nitric oxide production, reduced
endothelial oxidant stress, and improved endothelium-dependent vasodilation and early endothelial
progenitor cell-mediated endothelial repair. In contrast, these beneficial endothelial effects of HDL were
not observed in HDL from diabetic patients, which suggests markedly impaired endothelial-protective
properties of HDL. ER niacin therapy improved the capacity of HDL to stimulate endothelial nitric
oxide, to reduce superoxide production, and to promote endothelial progenitor cell-mediated endothelial
repair. Further measurements suggested increased lipid oxidation of HDL in diabetic patients, and a
reduction after ER niacin therapy. CONCLUSIONS: HDL from patients with type 2 diabetes mellitus
and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL
from healthy subjects. ER niacin therapy not only increases HDL plasma levels but markedly improves
endothelial-protective functions of HDL in these patients, which is potentially more important.
CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. Identifier: NCT00346970.
 Table 1
Characteristics of healthy subjects and diabetic patients 
Healthy
(n=10)
Diabetics
(n=33)
P -Value
Age [years] 65±10 60±11 0.22
Gender [m / f] 8/2 28/5 0.71
BMI [kg/m2] 27±3 33±4 0.0007
Waist circumference [cm] 91±11 116±13 < 0.0001
MAP [mmHg]
(MetS under antihypertensive therapy)
95±8 97±10 0.58
HbA1c [%] 5.4±0.5 6.6±1.0 0.0003
Fasting Glucose [mg/dL] 93±18 128±34 0.009
LDL Cholesterol [mg/dL]
(MetS under statin therapy)
145±26 110±27 0.001
HDL Cholesterol [mg/dL] 53±22 36±6 0.02
Triglycerides [mg/dL] 168±94 225±213 0.41
HDL Composition:
Cholesterol [mg/dL] 20.4±6.3 14.9±7.6 0.05
Triglycerides [mg/dL] 2.1±2.9 4.3±3.1 0.07
Protein [mg/dL] 65.5±22.1 57.4±12.2 0.22
BMI, body mass index
MAP, mean arterial pressure
n.s., not significant
Values expressed as mean ± SD
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Table 2
Characteristics of diabetic patients before and after placebo or extended-release niacin  treatment
Placebo (n=15) ERN (n=15)
Age [years] 62±9 58±11
Gender [m/f] 12/3 13/2
BMI [kg/m2] 34±5 32±4
Pre Post Pre Post P-Value
MAP [mmHg] 95±9 92±11 99±8 93±9 0.37
HbA1c [%] 7.1±1.0 6.9±1.0 6.3±0.9 6.5±0.8 0.18
Fasting Glucose [mg/dL] 134±38 130±28 123±31 127±31 0.32
LDL-Cholesterol [mg/dL] 112±31 101±29 107±24 101±28 0.96
HDL-Cholestrol [mg/dL] 35±7 33±5 36±6 42±5 0.001
Triglycedrides [mg/dL] 290±284 297±232 160±62 118±61 0.06
HDL Composition:
Cholesterol [mg/dL] 12.2±3.5 12.1±3.7 17.5±8.9 14.4±4.5 0.28
Triglycerides [mg/dL] 4.5±3.2 3.8±2.9 4.0±2.6 2.2±1.7 0.11
Protein [mg/dL] 55.9±8.9 59.2±11.8 55.8±12.3 58.7±14.1 0.82
Medication
ACE/ARB 10/15 09/15
ASS 12/15 10/15
Diuretic 05/15 03/15
Calcium-Antagonist 04/15 02/15
Beta-Blocker 13/15 10/15
Statin 15/15 15/15
Oral Antidiabetic Drug 4/15 05/15
 Insulin 3/15 02/15
Values are expressed as mean ± SD
The  P-values  relate  to  the  statistical 
analyses  of  changes  (i.e.  treatment 
effects)  of  the  ERN  vs.  the  Placebo 
group.
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